HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by DANIELS, S. E. Articles by VERBURG, K. M. Search for Related Content PubMed PubMed Citation Articles by DANIELS, S. E. Articles by VERBURG, K. M. Related Collections Pharmacology

JADA Continuing Education

Background. The authors conducted two studies to compare the analgesic efficacy and safety of the cyclooxygenase, or COX, -2–specific inhibitor, valdecoxib, with oxycodone/acetaminophen in patients who have undergone oral surgery.

Methods. In total, 205 eligible subjects in Study A and 201 in Study B were randomized to receive a single oral dose of valdecoxib (20 or 40 milligrams), a combination of oxycodone 10 mg/acetaminophen 1,000 mg or placebo. Eligible subjects experienced moderate-to-severe pain within six hours of surgery during which two or more impacted third molars were extracted. Analgesic efficacy was assessed over 24 hours or until the patient required rescue analgesia.

Results. In both studies, subjects receiving either dose of valdecoxib experienced a rapid onset of analgesia and (among those who received valdecoxib 40 mg) a level of pain relief comparable with that of those who received oxycodone/acetaminophen. Both valdecoxib doses had a significantly longer duration of analgesic effect than did oxycodone/acetaminophen. Pooled safety data demonstrated that each valdecoxib dose had a tolerability profile superior to that of oxycodone/acetaminophen and similar to that of placebo.

Conclusions. Orally administered valdecoxib is as rapidly acting and effective as oxycodone/acetaminophen, and it has a superior duration of analgesic effect in patients after oral surgery. Valdecoxib has a tolerability profile superior to that of oxycodone/acetaminophen.

Clinical Implications. The current standard of care for alleviating acute pain after oral surgery has rested largely on conventional nonsteroidal anti-inflammatory drugs or opioid/analgesic combination products. The studies reported here suggest that the COX-2–specific inhibitor valdecoxib offers an efficacious and safe alternative to other analgesics used to treat pain after oral surgery.

This article has been cited by other articles:

				E. F. Ekman, G. Ruoff, K. Kuehl, L. Ralph, P. Hormbrey, J. Fiechtner, and M. F. Berger The COX-2 Specific Inhibitor Valdecoxib Versus Tramadol in Acute Ankle Sprain: A Multicenter Randomized, Controlled Trial Am. J. Sports Med., June 1, 2006; 34(6): 945 - 955. [Abstract] [Full Text] [PDF]

				M. A. Huber and G. T. Terezhalmy The use of COX-2 inhibitors for acute dental pain: A second look J Am Dent Assoc, April 1, 2006; 137(4): 480 - 487. [Abstract] [Full Text] [PDF]

				M. SPINK, S. BAHN, and R. GLICKMAN Clinical implications of cyclo-oxygenase-2 inhibitors for acute dental pain management: Benefits and risks J Am Dent Assoc, October 1, 2005; 136(10): 1439 - 1448. [Abstract] [Full Text] [PDF]

				J. L. Apfelbaum, T. J. Gan, S. Zhao, D. B. Hanna, and C. Chen Reliability and Validity of the Perioperative Opioid-Related Symptom Distress Scale Anesth. Analg., September 1, 2004; 99(3): 699 - 709. [Abstract] [Full Text] [PDF]

				E. F. Ekman and L. A. Koman Acute Pain Following Musculoskeletal Injuries and Orthopaedic Surgery. Mechanisms and Management J. Bone Joint Surg. Am., June 1, 2004; 86(6): 1316 - 1327. [Full Text] [PDF]

				T. J. Gan, G. P. Joshi, E. Viscusi, R. Y. Cheung, W. Dodge, J. G. Fort, and C. Chen Preoperative Parenteral Parecoxib and Follow-Up Oral Valdecoxib Reduce Length of Stay and Improve Quality of Patient Recovery After Laparoscopic Cholecystectomy Surgery Anesth. Analg., June 1, 2004; 98(6): 1665 - 1673. [Abstract] [Full Text] [PDF]

				T. D. WARNER and J. A. MITCHELL Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic FASEB J, May 1, 2004; 18(7): 790 - 804. [Abstract] [Full Text] [PDF]

				K. Pavelka, D. P. Recker, and K. M. Verburg Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial Rheumatology, October 1, 2003; 42(10): 1207 - 1215. [Abstract] [Full Text] [PDF]

				N. M. Gajraj Cyclooxygenase-2 Inhibitors Anesth. Analg., June 1, 2003; 96(6): 1720 - 1738. [Full Text] [PDF]

				P. T. Leese, D. P. Recker, and J. D. Kent The COX-2 Selective Inhibitor, Valdecoxib, Does Not Impair Platelet Function in the Elderly: Results of a Randomized Controlled Trial J. Clin. Pharmacol., May 1, 2003; 43(5): 504 - 513. [Abstract] [Full Text] [PDF]